Epigenetic agents in combined anticancer therapy
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
29676175
DOI
10.4155/fmc-2017-0203
Knihovny.cz E-zdroje
- Klíčová slova
- anticancer treatment, combination therapy, epigenetic agents,
- MeSH
- antitumorózní látky farmakologie terapeutické užití MeSH
- DNA modifikační methylasy farmakologie MeSH
- epigeneze genetická účinky léků MeSH
- histonacetyltransferasy antagonisté a inhibitory MeSH
- histondemethylasy antagonisté a inhibitory MeSH
- histonové methyltransferasy antagonisté a inhibitory MeSH
- inhibitory histondeacetylas farmakologie terapeutické užití MeSH
- kombinovaná terapie metody MeSH
- lidé MeSH
- metylace DNA účinky léků MeSH
- nádory farmakoterapie genetika terapie MeSH
- objevování léků metody MeSH
- regulace genové exprese u nádorů účinky léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- antitumorózní látky MeSH
- DNA modifikační methylasy MeSH
- histonacetyltransferasy MeSH
- histondemethylasy MeSH
- histonové methyltransferasy MeSH
- inhibitory histondeacetylas MeSH
In the last decade, epigenetic drugs (such as inhibitors of DNA methyltransferases and histone deacetylases) have been intensively used for cancer treatment. Their applications have shown high anticancer effectivity and tolerable side effects. However, they are unfortunately not effective in the treatment of some types and phenotypes of cancers. Nevertheless, several studies have demonstrated that problems of drug efficacy can be overcome through the combined application of therapeutic modulates. Therefore, combined applications of epigenetic agents with chemotherapy, radiation therapy, immunotherapy, oncolytic virotherapy and hyperthermia have been presented. This review summarizes and discusses the general principles of this approach, as introduced and supported by numerous examples. In addition, predictions of the future potential applications of this methodology are included.
1st Faculty of Medicine Charles University Prague Kateřinská 32 121 08 Prague 2 Czech Republic
BIOCEV 1st Faculty of Medicine Charles University 252 50 Vestec Czech Republic
Citace poskytuje Crossref.org
Targeting of the Mitochondrial TET1 Protein by Pyrrolo[3,2-b]pyrrole Chelators
